DNA

March of Dimes Awards Dr. Dennis Lo the 2025 March of Dimes Richard B. Johnston, Jr., MD Prize

Recognized for discovery of cell-free fetal DNA in maternal blood and creation of noninvasive prenatal testing (NIPT), used by as…

2 weeks ago

TruDiagnostic Introduces Revolutionary Epigenetic Biomarker Proxies: New Diagnostic Approach Outperforms Traditional Lab Results

LEXINGTON, Ky., Dec. 17, 2024 /PRNewswire/ -- TruDiagnostic, a global leader in advanced epigenetic research, proudly announces a groundbreaking advancement in…

2 weeks ago

Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H’s REACT Program

Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders…

2 weeks ago

Alira Health Secures Up to $100M Growth Debt Facility from Symbiotic Capital to Propel Strategic Expansion and Patient-Enabled Innovation

FRAMINGHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alira Health, a global healthcare consulting and technology firm transforming the patient…

2 weeks ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate…

2 weeks ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and…

2 weeks ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate…

2 weeks ago

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

SUNNYVALE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for…

2 weeks ago

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting…

2 weeks ago

CellarisBio Announces “CHALLENGING TARGET AWARD” to Promote Innovation in Drug Discovery

SAN DIEGO, Dec. 16, 2024 /PRNewswire/ -- CellarisBio breaks ground with an announcement of "Challenging Target Award" to foster innovation…

3 weeks ago